Publicaciones en colaboración con investigadores/as de Ikerbasque, Fundación Vasca para la Ciencia (107)

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology

  2. Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma

    Gastroenterology, Vol. 166, Núm. 5, pp. 886-901.e7

  3. MCPIP1 Inhibits Hepatic Stellate Cell Activation in Autocrine and Paracrine Manners, Preventing Liver Fibrosis

    Cellular and Molecular Gastroenterology and Hepatology, Vol. 17, Núm. 6, pp. 887-906

  4. Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis

    Hepatology, Vol. 79, Núm. 2, pp. 269-288

  5. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  6. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes

    Scientific Reports, Vol. 13, Núm. 1

  3. Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease

    JHEP Reports, Vol. 5, Núm. 5

  4. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  5. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  6. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  7. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity

    FASEB Journal, Vol. 37, Núm. 11

  8. MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells

    Journal of Hepatology, Vol. 78, Núm. 2, pp. 364-375

  9. PFKFB4 Is a Metabolic Driver of HCC Progression and Chemoresistance Through ROS Mitigation

    Cellular and Molecular Gastroenterology and Hepatology

  10. Polycystic liver diseases: from molecular basis to development of effective treatments

    Revista Espanola de Enfermedades Digestivas

  11. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

  12. Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma

    Cancers, Vol. 15, Núm. 20

  13. miR-21-5p promotes NASH-related hepatocarcinogenesis

    Liver International, Vol. 43, Núm. 10, pp. 2256-2274

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121